143 recruiting. 143 Phase 3, 38 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 143 | Recruiting 143 |
| Phase 2 | 38 | Recruiting 38 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma JS203 in combination with gemcitabine and oxaliplatin, Rituximab in combination with gemcitabine and oxaliplatin - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 282 | 2026-10-08 | 2026-10-14 |
| Better Options for Lymphatic Filariasis Treatment MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole - Lymphatic Filariasis, Scabies | Phase 3 | Recruiting | Medicines Development for Global Health | 5100 | 2026-09-28 | 2026-10-07 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) Inotuzumab ozogamicin (INO), Blinatumomab - B-Cell Acute Lymphoblastic Leukaemia | Phase 3 | Recruiting | Charite University, Berlin, Germany | 750 | 2026-09-01 | 2026-10-26 |
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | Nurix Therapeutics, Inc. | 620 | 2026-08-03 | 2026-08-31 |
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-07-24 | 2026-10-27 |
| PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma 20 Gy Involved site radiotherapy, 30 Gy Involved site radiotherapy - Hodgkin Lymphoma | Phase 3 | Recruiting | Fondazione Italiana Linfomi - ETS | 518 | 2026-07-10 | 2026-08-27 |
| Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning - Astrocytoma, IDH-Mutant, Grade 3 | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 408 | 2026-06-24 | 2026-10-02 |
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) MK-1045, Rituximab, Rituximab biosimilar - Follicular Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-06-22 | 2026-10-26 |
| Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections Panzyga, 10% Intravenous Solution, Placebo - Hypogammaglobulinemia, Autoimmune Conditions | Phase 3 | Recruiting | Octapharma | 360 | 2026-06-10 | 2026-10-28 |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma SCTB35 injection, Rituximab, Lenalidomide - Follicular Lymphoma (FL) | Phase 3 | Recruiting | Sinocelltech Ltd. | 93 | 2026-06-09 | 2026-08-13 |
| Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities atorvastatin of dose level 1, atorvastatin of dose level 2, atorvastatin of dose level 3 - Kawasaki Disease, Coronary Artery Abnormalities | Phase 3 | Recruiting | Children's Hospital of Fudan University | 9 | 2026-06-08 | 2026-06-16 |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma SCTB35 injection, Rituxumab, Gemcitabine - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Sinocelltech Ltd. | 101 | 2026-06-04 | 2026-08-13 |
| Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP Chidamide, Entecavir Tablets - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 3 | Recruiting | Ou Bai, MD/PHD | 200 | 2026-05-30 | 2026-03-25 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-10-19 |
| A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome KP-001, Placebo - Venous Malformations, Lymphatic Malformations | Phase 3 | Recruiting | Kaken Pharmaceutical | 150 | 2026-05-13 | 2026-09-21 |
| A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma Gamunex-C, 10% Injectable Solution - Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Phase 3 | Recruiting | Grifols Biologicals, LLC | 49 | 2026-05-11 | 2026-10-01 |
| Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) Surovatamig - Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV | Phase 3 | Recruiting | AstraZeneca | 420 | 2026-05-05 | 2026-10-06 |
| Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL Zanubrutinib, Sonrotoclax, Computed Tomography - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 466 | 2026-04-30 | 2026-10-02 |
| ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Rocbrutinib, Pirtobrutinib - CLL / SLL, CLL (Chronic Lymphocytic Leukemia) | Phase 3 | Recruiting | Newave Pharmaceutical Inc | 306 | 2026-04-23 | 2026-08-11 |
Showing 20 of 143. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (19) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (19) · Leukemia, Lymphocytic, Chronic, B-Cell (18) · Lymphoma (16) · Lymphoma, Follicular (14) · Burkitt Lymphoma (11) · Neoplasms (11) · Lymphoma, Non-Hodgkin (9) · Leukemia (8) · Lymphoma, T-Cell, Peripheral (8) · Recurrence (8) · Hematologic Neoplasms (7) · Hodgkin Disease (6) · Infections (6) · Lymphoma, B-Cell (6)
Hemic and Lymphatic Diseases (143) · Immune System Diseases (128) · Lymphoproliferative Disorders (122) · Immunoproliferative Disorders (121) · Neoplasms by Histologic Type (118) · Neoplasms (114) · Lymphoma (68) · Lymphoma, Non-Hodgkin (59) · Hematologic Diseases (57) · Leukemia (40) · Leukemia, Lymphoid (40) · Lymphoma, B-Cell (32) · Pathologic Processes (29) · Pathological Conditions, Signs and Symptoms (29)
Rituximab (26) · Cyclophosphamide (20) · Vincristine (17) · Doxorubicin (14) · Prednisone (14) · Bendamustine Hydrochloride (12) · Dexamethasone (12) · blinatumomab (12) · venetoclax (11) · Cytarabine (10) · Methotrexate (10) · Prednisolone (10) · Gemcitabine (8) · Lenalidomide (8) · Daunorubicin (7)
Cancer Research UK (6) · Merck Sharp & Dohme LLC (6) · BeOne Medicines (5) · Monash University (5) · Alliance for Clinical Trials in Oncology (4) · AstraZeneca (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (3) · Fondazione Italiana Linfomi - ETS (3) · Memorial Sloan Kettering Cancer Center (3) · Novartis Pharmaceuticals (3) · Regeneron Pharmaceuticals (3) · Ruijin Hospital (3) · Assistance Publique - Hôpitaux de Paris (2) · Azafaros B.V. (2)
China (55) · United States (55) · Australia (39) · Italy (38) · United Kingdom (38) · France (36) · Spain (32) · Germany (31) · Canada (29) · Poland (26) · Belgium (24) · Netherlands (22) · Turkey (Türkiye) (22) · Czechia (21) · Brazil (20)
Matthew Krebs, Dr (5) · Xiaofan Zhu, MD (4) · Zoe McQuilten, Professor (4) · A. van Rhenen, MD (1) · Alessandro Pulsoni, MD (1) · Amos Burke (1) · Andrea Filippi, MD (1) · Anita Lawitschka, Assoc. Prof. MD (1) · Arend von Stackelberg, Dr. med., MD (1) · Barbara Eichhorst, MD, Prof. (1)
PMID 41671463, PMID 25113753, PMID 25482745, PMID 28516671, PMID 28782106, PMID 29072976, PMID 29189665, PMID 30115089, PMID 30240774, PMID 30694529, PMID 30980684, PMID 31123029, PMID 31236308, PMID 31911261, PMID 32589970, PMID 33152759, PMID 33242441, PMID 33332189, PMID 33394214, PMID 33738443, PMID 33974585, PMID 34387740, PMID 34524406, PMID 35129146, PMID 35292232, PMID 35501736, PMID 36044195, PMID 36427234, PMID 37141547, PMID 37717734, PMID 37738088, PMID 38070906, PMID 38294974, PMID 38309282, PMID 38390569, PMID 38662981, PMID 38841802, PMID 39007066, PMID 39602342, PMID 39875951, PMID 40135712, PMID 40186126, PMID 40513057, PMID 40739200, PMID 40820816, PMID 40926035, PMID 41259231, PMID 41353787, PMID 41522540, PMID 41749915
2023 (7), 2025 (6), 2017 (1), R01CA249467 (1), U10CA180820 (1), U10CA180821 (1), U10CA180886 (1), U10CA180888 (1), UG1CA189961 (1)